OBP-801
Also known as: OBP801, Spiruchostatin B analogue, YM753
Source OBP-801 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
OBP-801 (also known as YM753 or spiruchostatin B analog) is a cyclic depsipeptide HDAC inhibitor under investigation for solid tumors and hematologic malignancies. It has demonstrated potent antitumor activity in preclinical models, particularly against breast cancer and ovarian cancer, and has entered early-phase clinical trials in Japan and elsewhere.
Mechanism of Action
Selectively inhibits class I histone deacetylases (HDAC1, HDAC2, HDAC3, HDAC8), leading to hyperacetylation of histones, reactivation of silenced tumor suppressor genes, induction of cell cycle arrest, and apoptosis in cancer cells.
Routes of Administration
Goals & Uses
- Combination anticancer therapyOncologyLow
- Antitumor activity in solid tumorsOncologyModerate
- Epigenetic reprogramming of cancer cellsOncology/EpigeneticsModerate
- Hematologic malignancy treatmentOncologyLow
Contraindications
- Severe hepatic impairmentOrganModerateLiver function concerns
- Known hypersensitivity to cyclic depsipeptide HDAC inhibitorsAllergyHigh
- Severe cardiac arrhythmia or QTc prolongationCardiovascularHigh
Adverse Effects
- ThrombocytopeniaHematologicCommonLow platelet count
- QTc prolongationCardiacUncommon
- Nausea/vomitingGastrointestinalCommon
- NeutropeniaHematologicUncommonLow neutrophil count
- FatigueGeneralCommonLow energy or tiredness
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
Drug Interactions
- Anticoagulants (e.g., warfarin)Moderate
- QTc-prolonging agents (e.g., antiarrhythmics, certain antipsychotics)High
- Strong CYP3A4 inhibitorsModerate
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- BreastfeedingReproductiveAbsolute
Regulatory Status
- European UnionUnknownNo EMA approval; clinical activity primarily in Japan.
- United StatesInvestigationalNo FDA approval; IND status not publicly confirmed; investigational use only.
- United KingdomUnknownNo MHRA approval on record.
OBP-801 has been evaluated in Phase I clinical trials primarily in Japan. It does not hold approved status in any major jurisdiction as of the available data. It is a research/investigational compound.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is OBP-801?
OBP-801 (also known as YM753 or spiruchostatin B analog) is a cyclic depsipeptide HDAC inhibitor under investigation for solid tumors and hematologic malignancies. It has demonstrated potent antitumor activity in preclinical models, particularly against breast cancer and ovarian cancer, and has entered early-phase clinical trials in Japan and elsewhere.
What is OBP-801 used for?
OBP-801 is educationally associated with: Combination anticancer therapy, Antitumor activity in solid tumors, Epigenetic reprogramming of cancer cells, Hematologic malignancy treatment. Educational only — not medical advice.
How is OBP-801 administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of OBP-801?
Reported adverse effects include: Thrombocytopenia, QTc prolongation, Nausea/vomiting, Neutropenia, Fatigue, Elevated liver enzymes. This list is not exhaustive — consult a qualified clinician.
Who should avoid OBP-801?
Recorded contraindications: Severe hepatic impairment, Known hypersensitivity to cyclic depsipeptide HDAC inhibitors, Severe cardiac arrhythmia or QTc prolongation. Consult a qualified clinician before use.